

## **Summary of the risk management plan for Protaphane (human insulin)**

This is a summary of the RMP for Protaphane. The RMP details important risks of Protaphane, how these risks can be minimised, and how more information will be obtained about Protaphane's risks and uncertainties (missing information).

Protaphane's Summary of Product Characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals and patients on how Protaphane should be used.

This summary of the RMP for Protaphane should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all of which is part of the EPAR.

Important new concerns or changes to the current ones will be included in updates of Protaphane's RMP.

### **I. The medicine and what it is used for**

Protaphane is authorised for the treatment of diabetes mellitus. It contains human insulin as the active substance and it is given by subcutaneous route.

Further information about the evaluation of Protaphane's benefits can be found in Protaphane's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpages ([EPAR link Protaphane](#)).

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Protaphane, together with measures to minimise such risks and the proposed studies for learning more about Protaphane's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorised pack size – the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly.
- The medicine's legal status – the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about AEs is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## **II.A List of important risks and missing information**

Important risks of Protaphane are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Protaphane. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## **II.B Summary of important risks**

No risks of Protaphane need special risk management or pharmacovigilance activities for further characterisation.

## ***II.C* Post-authorisation development plan**

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies that are conditions of the marketing authorisation or specific obligation of Protaphane.

### **II.C.2 Other studies in post-authorisation development plan**

No studies are required for Protaphane.